FFA-guided Grouping For Choroidal Neovascularization(CNV)and The Therapeutic Effect After Intravitreal Ranibizumab

Objective: The relationship between choroidal neovascularization(CNV) of different type through FFA and efficacy of intravitreal ranibizumab was observed and analyzed, which may provide individualized treatment in patients with exudative AMD.Methods: It was a prospective study. The diagnosed exudative age related macular degeneration(e AMD) patients(totally 30) who were treated with IVR on a monthly treatment regimen from May 2014 to January 2015 in the Subsidiary First Hospital were included in the study. According to the different condition of the FFA, we set up two treatment groups, that was, typical groups(include 15), atypical groups(include 15).Age, gender, previous history, intraocular pressure(IOP), best-corrected visual acuity(BCVA), central macular thickness(CMT) that detected by examination of visual acuity and optical coherence tomography(OCT) were collected. All patients received intravitreal Ranibizumab(0.5mg/0.05ml),once a month for three months. The changes of two groups’ BCVA and CMT were recorded during follow-up period. SPSS17.0 was used to analysis two groups’ dates. Probability less than 0.05 was considered to be statistically significant.Results: Thirty patients were included in this study, 13 males(13 eyes) and 17females(17 eyes). In typical group, median BCVA(Log MAR) were improved from1.06±0.50 to 0.66±0.42(P=0.000); median CMT were decreased from(510.60±208.21)μm to(334.73±137.46) μm(P=0.000) after 3 months follow-up. In atypical groups, median BCVA(Log MAR) were improved from 0.81±0.29 to 0.64±0.36(P=0.034); median CMT were decreased from(515.27±181.97) μm to(320.53±167.72)μm(P=0.001).In group typical and atypical, the median BCVA were 0.83±0.32 and0.68±0.23(P=0.148), the CMT were(426.87±180.64) μm and(427.20±147.75) μm(P=0.996) at 1 day; the median BCVA were 0.88±0.48 and 0.67±0.33(P=0.172), the CMT were(398.20±136.99) μm and(368.20±195.74) μm(P=0.631) at 1 month; the median BCVA were 0.79±0.45 and 0.64±0.34(P=0.318), the CMT were(388.60±155.19) μm and(323.07±153.99) μm(P=0.255) at 2 month; the median BCVA were 0.66±0.42 and0.64±0.36(P=0.911), the CMT were(334.73±137.46) μm and(320.53±167.72) μm(P=0.802) at 3 month. No ocular and systemic complications were occurred during 3 mouths.Conclusion: First, intravitreal Ranibizumab for the treatment of kinds of CNV caused by e AMD was effective and safe.Second, there were no significant differences in effectiveness between two groups.